MS, ALS, MG Cav MOA

Glatiramer

Bystander suppression- peripheral Th2 cells & prevent BBB

Teriflunomide

JAK-STAT & DODH (-)s preventing inflammation & creation of cellular components

Dimethyl fumarate

Th2 & pERK1 (-)

Cladribine

Interferes w/ DNA synthesis and repair

Fingolimod

(-) S1P from binding to receptors stopping T-cells from crossing the endothelial barrier

Mitoxanterone

(-) B cell, T cell, & macrophage proliferation, impairs antigen presentation, and (-)s secretion of many cytokines

CD20 mAbs (Ocrelizumab, Ofatumab, Ublituximab)

Deplete B cells via:

Ab-dependent cell mediated cytotoxicity

Complement-mediated cytotoxicity

Apoptosis induction

Natalizumab

VCAM1 (-) which prevents T cells from adhering & penetrating BBB

Altemtuzumab

CD52 (-) which prevents immune cells from performing functions leading to degradation

Riluzole

Glu antagonist decreasing Glu release and increasing Glu uptake

Edaravone

Free radical scavenger (antioxidant)

Tofersen

Antisense oligonucleotide (ASO) that targets RNA produced by mutated SOD1 genes (stops toxic SOD1 protein production)

Pyridostigmine

AChE (-)

Rozanolixizumab

Human IgG1 Fc fragment that targets FcRn preventing the recycling of Abs

Zilucoplan

Complement C5 (-) preventing the cleavage of C5 to C5a and C5b which are used to form MAC (decreased inflammatory mediators)